Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Amer Zeidan, MBBS, MHS, Yale Cancer Center, New Haven, CT, talks about the polo-like kinase 1 (PLK1) inhibitor onvansertib in combination with low-dose cytarabine or decitabine in R/R acute myeloid leukaemia (AML). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.